Frevecitinib Clinical Trials (2026): 1 Studies for Severe Asthma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 Frevecitinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Severe Asthma) and 512 total planned enrollment. 1 Frevecitinib clinical trial is actively recruiting at 9 U.S. sites across 5 states. Most recent activity: NCT07532265 (Nov 2027).
Where to Participate: All Frevecitinib Trial Sites in the U.S. (9 sites across 5 states)
Every actively recruiting Frevecitinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Research site | Lancaster93534 | NCT07532265 | Map |
| CA | Research site | San Jose95117 | NCT07532265 | Map |
| FL | Research site | Miami33137 | NCT07532265 | Map |
| FL | Research site | Tampa33607 | NCT07532265 | Map |
| NC | Research site | Charlotte28277 | NCT07532265 | Map |
| SC | Research site | Rock Hill29732 | NCT07532265 | Map |
| TX | Research site | Dallas75225 | NCT07532265 | Map |
| TX | Research site | Houston77099 | NCT07532265 | Map |
| TX | Research site | San Antonio78258 | NCT07532265 | Map |
Frevecitinib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P2 | 1 | 1 |
Recruiting Frevecitinib clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07532265 | PANAIRAMAA Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma | P2 | Severe Asthma | 512 | Jul 2026 |
Frevecitinib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| PANAIRAMA | NCT07532265 | P2 | recruiting | Severe Asthma | 512 | — |
All Frevecitinib trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07532265 | PANAIRAMA | A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma | P2 | recruiting | 512 | Kinaset Therapeutics Inc | Jul 2026 |
Frevecitinib clinical trials: frequently asked questions
- How many Frevecitinib clinical trials are there?
- 1 Frevecitinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are Frevecitinib clinical trials recruiting in 2026?
- Yes — 1 Frevecitinib trial is actively recruiting in 2026, with 9 U.S. sites across 5 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Frevecitinib being studied for?
- Frevecitinib is being studied for Severe Asthma. The trials are grouped by indication on this page.
- What phase is Frevecitinib in?
- Frevecitinib clinical trials span 1 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Frevecitinib clinical trials?
- The lead sponsor across the most Frevecitinib trials is Kinaset Therapeutics Inc. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Frevecitinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: